Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

MidCap Financial LLC

MidCap Financial is a commercial finance firm that was founded in 28 with offices in Bethesda MD Chicago IL and Los Angeles CA. The firm focuses on providing debt financing solutions to healthcare companies. The firm generally provides loans of around $15 million and is involved in approximately 15 new deals each year. The firm considers companies located around globe.
Website:
www.midcapfinancial.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Josh Groman
Managing Director 
James Taylor
Director 

MitoDys Therapeutics United Kingdom

MitoDys Therapeutics is a start-up drug discovery company that has developed a highly innovative platform to uncover polypharmacological drugs with existing safety profiles that can be repositioned to a new indcation.  The company focuses on the discovery of disease-modifying drugs for neurodegenerative diseases; particularly Parkinson's disease, ALS and MSA.

Website:
www.mitodys.com
Year Founded
2012
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Technology Overview
Network Pharmacology platform combined with pluripotent stem cell-derived assays
Current Financing Needs
$1m
Current Timeline
12-18 months to validated candidate
Current Investors
Angels and Charitable foundations
IP Status
None yet...focused on drugs at the end of the proecess
Management Team Highlights
Highly experienced individuals from Industry and finance
Steven Zimmer
CEO 

MP Healthcare Venture Management, Inc. United States

MP Healthcare Ventures is the corporate venture arm of Mitsubishi Tanabe Pharma founded in 2006 and based in Boston Massachusetts. The firm is looking to provide equity capital to seed and venture stage companies in the life science space. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year. The firm will invest in companies located anywhere around the world.

Website:
http://www.mp-healthcare.com
Year Founded
2006
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Capital Structure Preference
Investment Stage Preference
Tetsuro Iwata
Senior Manager 

MyeloRx United States

MyeloRx is a northern California based biotechnology company. Our lead compound, MRx102, is a small molecule inhibitor of RNA polymerase II. Molecules related to MRx102 have shown clinical efficacy in AML patients in Europe and China.  MRx102 is covered by issued composition of matter patents in the U.S., E.U., China and Japan.  While AML is the initial indication, MRx102 has also been found active in stringent models of pancreatic and lung cancer. Our collaborators include clinical oncologists from MD Anderson Cancer Center, JHU School of Medicine and City of Hope Medical Center. R&D activities have been funded primarily by a $2M NCI SBIR contract. Our strong scientific and management team is lead by Dr. John Musser; it has brought multiple products to market. We are seeking funding to complete an IND which is projected to take less than a year based on the extensive studies completed to date (manufacturing, formulation, toxicology/ PK in rats and dogs etc.)  and a Phase 1 clinical trial in AML patients.

 

Website:
www.myelorx.com
Year Founded
2007
Main Sector
Biotech Subsector
Indication
Technology Overview
The lead compound is termed MRx102. It is a prodrug of a purified natural product triptolide that has shown clinical activity in patients with acute myeloid leukemia (AML). Intellectual property MRx102 is covered by issued matter patents in the U.S., E.U., Japan and China. Molecular target The molecular target of the natural product, triptolide, is XPB, a subunit of the transcription factor TFIIH. Binding of XPB by triptolide leads inhibition of transcriptional activation resulting in the blockade of a number of signaling pathways that drive cancer cell proliferation. Safety Triptolide and earlier prodrugs of triptolide have shown toxicity in a variety of clinical studies. We therefore set out to design and develop a safe prodrug, viz. MRx102, using the learning from these earlier studies. In a direct comparative toxicology study performed in rats MRx102 was at least 20 times safer than triptolide. This was due to a favorable pharmacokinetic profile seen both in rats and dogs. Pilot toxicology/PK studies have been completed in rats and dogs; NOAELs have been determined in both species. Thought Leader Studies with MRx102 In collaboration with Dr. Michael Andreeff of the MD Anderson Cancer Center we demonstrated that MRx102 was extremely potent in killing human blast cell and stem cell populations from AML patients. The activity against the stem cell populations may indicate an activity in preventing relapse in these patients. MRx102 was likewise effective in a variety of in vivo xenograft models of AML. Dr. James Eshleman and his colleagues from the JHU School of Medicine have demonstrated the activity of MRx102 in killing pancreatic cancer cells having a variety of genetic abnormalities. Dr. Dan Raz of the City of Hope Medical Center has shown MRx102 effective in models of non-small cell lung cancer and identified a potential biomarker for susceptible cells. Current status MyeloRx has completed a $2M NCI Fast Track SBIR contract that enabled many preclinical activities required for an IND filing. Major remaining activities include the GMP manufacture of drug substance, performance of GLP toxicology in rats and dogs and then completion of the clinical plan for Phase 1 studies in AML and solid tumors. These could be completed to allow IND filing in less than a year.
Alliance & Collaborations
Option agreement for China territories
Current Financing Needs
$5-7M for IND filing/Phase 1 trial
Current Timeline
IND completion in less than one year
IP Status
Issued matter patents worldwide
Recent Milestones
Completion of tox/PK studies in rats/dogs
Neil Ackerman
Vice President Business Development 
John Musser
CEO